Fresenius Medical Care launches first tranche of its share buyback program of up to EUR 600 million

BAD HOMBURG, Germany, May 28, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced the launch of the first tranche of its new share buyback program with a total volume of around EUR 1 billion. The first tranche, amounting up to EUR 600 million, was initiated today and is expected to be completed by December 15, 2026.

PRNewsWire • May 28, 2026

Fresenius Medical Care highlights new renal research and innovation at ERA Congress 2026

Hemodiafiltration (HDF) research reinforces Fresenius Medical Care's continued leadership in advancing evidence-based dialysis care and treatment personalization New research focuses on applying real-world evidence, patient-centered outcomes and artificial intelligence across dialysis modalities and continuity of kidney care A preview of kinexus, a unified digital platform intended to support home dialysis programs by connecting therapy management and care workflows BAD HOMBURG, Germany, May 27, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with kidney diseases, presents new research highlighting ongoing innovation at the European Renal Association (ERA) Congress 2026, June 3-6 in Glasgow, Scotland, and virtually. The Company highlights advancements including new hemodiafiltration research that reaffirm its leadership in evidence based and personalized dialysis care, real-world evidence to strengthen patient centered outcomes across dialysis modalities, and the application of artificial intelligence (AI) to improve patient outcomes.

PRNewsWire • May 27, 2026

Fresenius Medical Care announces new share buyback program with a total volume of around EUR 1 billion with phased execution over 12 months

Total volume of the share buyback is around EUR 1 billion over 12 months Share buyback expected to begin in the near future BAD HOMBURG, Germany, May 26, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, intends to execute a new share buyback program with a total volume of around EUR 1 billion. The program shall be executed in tranches over a period of 12 months from its start.

PRNewsWire • May 26, 2026

Fresenius Medical Care Annual General Meeting: Strengthening performance and advancing innovation in kidney care

Shareholders approve proposed dividend of EUR 1.49 per share FME Reignite strategy launched in 2025 successfully drives the next phase of value creation 5008X CAREsystem introduced in U.S. clinics; full U.S. commercial launch underway in 2026 EUR 1 billion share buyback program successfully completed, and a new authorization granted to support the Company's capital allocation framework which includes share buyback programs BAD HOMBURG, Germany, May 21, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has completed a milestone year marked by significant improvements in profitability. Over the past three years, the Company has successfully delivered on its mid‑term financial and strategic targets set for 2025.

PRNewsWire • May 21, 2026

Fresenius Medical Care Reappoints Chief Financial Officer Martin Fischer

BAD HOMBURG, Germany, May 20, 2026 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care AG, the world's leading provider of products and services for individuals with renal disease, today has reappointed Chief Financial Officer (CFO) and Management Board Member Martin Fischer (49) for a period of five years until 2031. Michael Sen, Chairman of the Supervisory Board, commented, "Martin Fischer has demonstrated strong and consistent leadership and has further strengthened Fresenius Medical Care's governance, transparency, and financial discipline.

PRNewsWire • May 20, 2026

The Broyhill Q1 2026 Portfolio Strategy And Positioning

Valvoline was Broyhill's largest contributor in the quarter, as the underlying unit economics are intact, while unit growth, service mix, and price continue moving in the same direction. Honeywell management accelerated the aerospace spin-off to the end of June, leaving behind a pure-play automation business that Broyhill believes is worth meaningfully more than the whole. Large pharma is structurally reliant on IQVIA's clinical trial architecture and proprietary data assets, and Broyhill thinks it is highly unlikely that AI can automate away the FDA approval process.

Seeking Alpha • May 15, 2026

FMS Stock Rises Despite Q1 Earnings & Sales Miss, Margins Expand

Fresenius Medical's shares rise after Q1 earnings miss estimates as margin expansion and FME25+ savings support operating income growth.

Zacks Investment Research • May 6, 2026

Fresenius Medical Care's revenue falls in Q1 as weak dollar takes toll

Fresenius Medical Care said ​on Tuesday its ‌revenue fell 6% in the first ​quarter of ​2026, weighed down by ⁠significant currency ​effects, mainly from ​the weak U.S. dollar, and recent divestitures.

Reuters • May 5, 2026

Fresenius Medical Care Posts Lower Net Profit on One-Off Costs

The dialysis specialist started restructuring its U.S. network by exiting 64 of up to 100 clinics.

WSJ • May 5, 2026

Fresenius Medical Care AG (FMS) Q1 2026 Earnings Call Transcript

Fresenius Medical Care AG (FMS) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 5, 2026